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Abstract
Background: Thyroid-stimulating hormone (TSH) promotes expression of thyroid hormones which are essential for
metabolism, growth, and development. Second-line drugs to treat tuberculosis (TB) can cause hypothyroidism by
suppressing thyroid hormone synthesis. Therefore, TSH levels are routinely measured in TB patients receiving second-line
drugs, and thyroxin treatment is initiated where indicated. However, standard TSH tests are technically demanding for many
low-resource settings where TB is prevalent; a simple and inexpensive test is urgently needed.
Methods: As a proof of concept study TSH was measured in routinely collected sera at the University Medical Center
Utrecht, Netherlands, using the TSH-CHECK-1 (VEDALAB, Alenc ¸on, France), a lateral-flow rapid immunochromatographic
assay with a TSH cut-off value of 10 mIU/mL, the standard threshold for initiating treatment. These results were compared
with TSH levels measured by a reference standard (UniCel DXi 800 imunoassay system, Beckman Coulter, USA). Sensitivity,
specificity, and likelihood ratios were then calculated.
Results: A total of 215 serum samples were evaluated: 107 with TSH values ,10 mIU/mL and 108 with values $10 mIU/mL.
TSH-CHECK-1 test sensitivity was found to be 100.0% (95% CI: 96.6–100.0) and specificity was 76.6% (95% CI: 67.5–84.3).
Predictive values (PV) were modelled for different levels of prevalence. For a prevalence of 10% and 50%, the positive PV
was 32.2% (95% CI: 25.0–39.7%) and 81.1% (95% CI: 75.0–85.5%), respectively; the negative PV was 100% (95% CI: 98.9–
100%) and 100% (95% CI: 91.3–100%) respectively.
Discussion/Conclusions: The TSH-CHECK-1 rapid test was practical and simple to perform but difficult to interpret on weak
positive results. All sera with TSH$10 mIU/mL were correctly identified, but the test lacked sufficient specificity. Given its
excellent negative PV in this evaluation, the test shows promise for ruling out hypothyroidism. However, so far it appears
that samples testing positive with TSH-CHECK-1 would require confirmation using another method.
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Introduction
Multi-drug resistant tuberculosis is a growing problem especially
in resource-limited settings and typically requires treatment for at
least two years with drugs that can have significant side effects [1–
5]. Second-line anti-tuberculosis (TB) drugs such as para-
aminosalicylic acid, ethionamide, and prothionamide are known
to cause hypothyroidism in up to 58% of patients by inhibiting
thyroid hormone synthesis through inhibiting the uptake of iodine
into thyroid cells and by inhibiting thyroid peroxidise [6–13].
These high rates of hypothyroidism have been confirmed in two
TB clinics run by Me ´decins Sans Frontie `res where about 50% of
patients show hypothyroidism after 6 months on these drugs.
Since the symptoms of hypothyroidism can be subtle, the World
Health Organization recommends that patients on these second-
line TB drugs are screened for hypothyroidism every 6 months, or
sooner if symptoms arise [14].
TSH is produced in the adenohypophysis and promotes
production of the thyroid hormones T3 and T4, which are
essential for growth and development of the nervous system.
Thyroid hormones also affect the synthesis, mobilization and
degradation of fat and increase the number of cell surface
catecholamine receptors, which in turn affects heart rate. TSH is a
marker for thyroid function, and a normal TSH level (,5 mIU/
mL) indicates proper thyroid function. Thyroxin is given as
therapy for hypothyroidism once a TSH level of 10 mIU/mL is
reached [15].
Although monitoring TSH levels in MDR-TB patients is
important for managing drug side effects, it can be extremely
challenging in low-resource settings: the standard ELISA test
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costly. A simple, inexpensive test that could substitute for the
ELISA assay in identifying patients who need thyroxin treatment
(i.e., those with TSH.10 mIU/mL) would greatly improve the
monitoring and treatment of hypothyroidism in low-resource
settings.
The TSH-CHECK-1 rapid test is a two-band immunochro-
matographic diagnostic test developed to screen neonates for
hypothyroidism; unlike other TSH rapid tests, it is adjusted to
detect a TSH level of 10 mIU/mL (rather than 5 mIU/mL, the
standard for a diagnosis of hypothyroidism, but not yet requiring
treatment). According to the manufacturer, there is a range of
620% around this cut-off (i.e. 8–12 mIU/mL) when tests are read
10–15 minutes after the addition of sample and diluents.
Specificity is claimed to be .95%.
These properties led us to hypothesize that TSH-CHECK-1
could potentially replace the ELISA test in identifying TB patients
on second-line therapy and whose TSH levels have reached the
point (10 mIU/mL) where thyroxin treatment should begin. We
therefore conducted a test-of-concept study using samples from the
Netherlands to assess the accuracy of TSH-CHECK-1 against the
ELISA reference standard in diagnosing TSH levels above versus
below the treatment initiation threshold.
Methods
Study design
This study used a nested-case control design to compare the
TSH-CHECK-1 rapid test to an immunoassay using chemilumi-
nescent detection technology.
The sample size of 96 positive (TSH levels $10 mIU/mL) and
96 negative (TSH levels ,10 mIU/mL) samples was calculated
based on an estimated 90% sensitivity and 90% specificity with a
precision of 6%. Samples were consecutively selected from
specimens collected routinely at the Laboratory of Endocrinology
in the Department of Clinical Chemistry and Haematology at the
University Medical Center Utrecht (UMCU), the Netherlands
until the total of 96 ‘positive’ and ‘negative’ samples was reached.
Test platform and procedure
TSH-CHECK-1 (whole-blood pediatric version, VEDALAB,
Alenc ¸on, France; reference number 21103) is a lateral-flow rapid
immunochromatographic test in cassette format. The device must
be stored at 4–30uC and 25 ml of serum/plasma or 50 ml of whole
blood are required to perform the test. A negative result (i.e.
TSH,10 mIU/mL) is indicated by the presence of a single
coloured band in the control zone, while a positive result is
denoted by two clearly distinguishable bands. The test is
inconclusive if no line appears.
TSH-CHECK-1 tests were carried out according to the
manufacturer’s instructions on serum within two days of
collection. Results were initially read by the technician who
performed the test, and then by one subsequent reader. All readers
were blinded to the results of the reference test and to one other’s
readings. Consensus between the latter two readers was considered
a definitive result. If there was no consensus, the result from the
first reader was used; the dissenting reading was used to assess
inter-reader reproducibility.
Reference method
All samples were analyzed with the UniCel DXi 800 analyzer
(Beckman Coulter, Brea, CA, USA) according to the manufac-
turer’s recommendations. The precision of the TSH analysis on
the UniCel DXi 800 analyzer is 5–8%.
Ease of use
Two experienced laboratory technicians reported on the ease of
use of the TSH-CHECK-1 test using a standardized question-
naire.
Statistical analysis
Data was entered into an Excel file and analyzed using Stata 9.0
(Stata Corporation, College Station, Texas, USA). Sensitivity of
TSH-CHECK-1 was estimated as the proportion of positive
specimens detected among samples with TSH$10 mIU/mL, as
measured by the reference test; specificity was the proportion of
negative specimens detected among those with TSH,10 mIU/mL
according to the reference test. Likelihood ratios (LR) were
calculated using the following formulas:
LRz~sensitivity= 1{specificity ðÞ
and
LR{~ 1{specificity ðÞ =sensitivity:
Finally, the positive and negative predictive values were modelled
using the estimated sensitivities and specificities for different
hypothetical prevalence values. All parameters were estimated
with their 95% confidence intervals (CI). Inter-reader reproduc-
ibility was measured using the kappa coefficient.
Ethics statement
The ethics review board of the UMCU examined the study
protocol in accordance with the ‘Wet Maatschappelijke Onder-
steuning’ (WMO, the Dutch law regulating scientific and medical
research) and gave permission to conduct the study without
requiring patient consent, since the research used only leftover
material (i.e. did not require additional sample collection).
Results
Samples
A total of 215 serum samples collected during July–October
2010 were selected for the study: 107 had reference TSH values
,10 mIU/mL and 108 had values $10 mIU/mL. The median
TSH value was 10 mIU/mL (IQR: 2.3–19). The median TSH
among patients with reference TSH values ,10 mIU/mL was
2.3 mIU/mL (IQR: 1.4–4.3), and among patients with TSH values
.10 mIU/mL the median was 19 mIU/mL (IQR: 13–51.6). The
mean patient age was 48 years.
Sensitivity, specificity and predictive values
Compared with the reference standard, sensitivity of the TSH-
CHECK-1 test was 100.0% (95% CI: 96.6–100.0) and specificity
was 76.6% (95% CI: 67.5–84.3) (Table 1). The positive likelihood
ratio (LR+) was 4.3 (95% CI: 3.0–6.0) and the negative likelihood
ratio (LR2) was 0.01 (95% CI: 0.0–0.1). Positive and negative
predictive values were calculated based on several different
hypothetical prevalence levels (Table 2).
Quantitative characterization of TSH-CHECK-1 (Band
intensities)
Negative, faint-positive, and strong-positive results were com-
pared against quantitative TSH levels (Figure 1). Faint positives
were found in 36/133 (27.1%) of the positive samples with the
TSH-CHECK-1 test when results were read after exactly
15 minutes; these samples showed reference test levels ranging
Diagnostic Accuracy TSH-CHECK-1
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turned strongly positive when they were read at 30 minutes; only
5.3% of tests continued to show faint lines.
TSH levels were significantly different between negatives, faint
positives, and strong positives (Kruskall Wallis, P,0.001).
Inter-reader reliability
Inter-reader reliability for both positive and negative results was
high, with 99.5% agreement between the two readers, and a kappa
value of 0.99. For strong band intensities, all readings were
identical.
Ease of use
Based on the results of a questionnaire, we found that laboratory
technicians viewed the TSH-CHECK-1 test as practical and
simple to perform and the package insert as informative and easy
to understand. However, they encountered difficulties in the
interpretation of test results, which often appeared as faint but
discernible. Faint lines were considered positive since they were
clear and distinct, albeit weak. Another problem was that 5/215
(2.3%) of the pipettes delivered with the kit were defective (i.e.
leakage) and had to be discarded.
Discussion
This is, to our knowledge, the first evaluation of diagnostic test
accuracy with the TSH-CHECK-1 rapid test (pediatric version).
Our aim in this test-of-concept study was to do an initial
assessment, in a readily accessible population and setting, of the
test’s accuracy in distinguishing samples with TSH levels above
10 mIU/mL (the treatment threshold) from those below this level.
We found that TSH-CHECK-1 has an excellent sensitivity but
only moderate specificity in identifying patients with TSH levels
above the cut-off point. Furthermore, 5% (11/215) of patients with
TSH levels below the cut-off and within the normal range
(,5 mIU/mL) would have been misclassified as eligible for
treatment using this test.
This sub-optimal specificity could be due to a variety of
factors. Certain clinical factors (e.g. laboratory values) are known
to interfere with the TSH-CHECK-1 test and may cause false-
positive results; these include high levels of rheumatoid factor
or C-reactive protein (CRP), neither of which were measured
here. Both should be incorporated into future evaluations to
investigate possible cross-reactivity with the TSH-CHECK-1
test.
Technical issues might also play a role, some of which are
potentially resolvable. Most false positive results came from tests
showing faint lines, raising the notion that a scanning device such
as the EASY READER (VEDALAB, France), which has a high-
resolution digital camera and can yield quantitative or semi-
quantitative data from the test lines’ absorbance values, might
improve accuracy in interpreting ambiguous tests. We did not use
this device in our evaluation, since its relatively high cost and
requirement for a dependable supply of electricity limit its
usefulness in the lowest-resource settings where a TSH rapid test
is most needed.
Another factor that lowers test specificity might be inaccuracies
from using the pipetting devices furnished in the rapid test kits;
these were less accurate than the built-in calibrated transfer
pipettes used in the UniCel DXi 800 imunoassay system, the
reference system.
Finally, this evaluation was conducted as a proof of concept
study on characterized clinical specimens from a population that is
not representative of the population in which the test is intended to
be used. It needs to be repeated on consecutive specimens in the
target population, i.e. in TB patients receiving second line therapy
in a resource-limited setting. Further evaluation should also
include a cross-sectional study design, which is considered a more
rigorous test of diagnostic accuracy - although the nested case
study design used here, when properly applied, is recognized as a
reasonably accurate (and much faster and less expensive) initial
screen to determine whether a diagnostic test merits further
assessment [16,17].
In conclusion, the TSH-CHECK-1 is an easy-to-use rapid
diagnostic test suitable for use in low-resource settings. With an
Table 2. Positive and negative predictive values based on
variable prevalences of TSH level .10 mIU/mL.
Prevalence
Positive Predictive
Value (95% CI)
Negative Predictive
Value (95% CI)
5% 18.4% (13.8–24.1) 100% (99.5–100)
10% 32.2% (25.0–39.7) 100% (98.9–100)
20% 51.7% (42.9–59.7) 100% (97.7–100)
30% 64.7% (56.3–71.7) 100% (96.1–100)
40% 74.0% (66.7–79.8) 100% (97.7–100)
50% 81.1% (75.0–85.5) 100% (91.3–100)
doi:10.1371/journal.pone.0033704.t002
Table 1. Accuracy of TSH-CHECK-1 test compared against
reference standard with .10 mIU/mL as cut-off level for a
positive results.
TSH-CHECK-1
UniCel DXi 800 Positive Negative Total
Positive 108 0 108
Negative 25 82 107
Total 133 82 215
doi:10.1371/journal.pone.0033704.t001
Figure 1. Negative, weak positive, and strong positive test
results versus quantitative TSH level (TSH units: mIU/mL).
doi:10.1371/journal.pone.0033704.g001
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the test could be used to rule out hypothyroidism in second-line
TB patients. However, samples that test positive on the TSH-
CHECK-1 test should be confirmed using another method. Future
studies need to be performed to confirm the good performance as
a rule-out test in the intended target population, as well as to
investigate the potential use of the associated quantitative reader to
alleviate the need for a confirmatory test using more sophisticated
techniques.
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